{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"6.4","value":"4.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \\>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. PFS is defined as time from treatment start until disease progression met by RECIST 1.1 or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240mg IV + Ramucirumab 8mg/kg IV\n\nNivolumab: Nivolumab 240mg, IV over 30 minutes.\n\nRamucirumab: 8mg/kg, IV over 60 minutes.","id":"OG000","title":"Nivolumab + Ramucirumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time of treatment start until the criteria for disease progression or death, up to a maximum of 23 months.","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}